Court blocks aspects of surprise billing rule

Anthony Vecchione | | Health Exec | Policy & Regulations
Judge bangs gavel

In what is being viewed as a victory for doctors, a federal judge eliminated vital parts of the no surprise act rule, according to a report in The Hill.

Judge Jeremy D. Kernodle set aside parts of a recent rule that creates a new federal dispute resolution (IDR) process. The process is mandated under the No Surprises Act (NSA), a federal law that offers patients protection from the most common types of surprise out-of-network bills.

While Kernodle did not touch the IDR process, he did set aside parts of the IDR regulations that dictate how much health insurers can pay doctors, The Hill reported.

In his decision, Kernodle wrote: “In sum, the court holds that plaintiffs have standing to challenge the departments’ September 2021 interim final rule implementing the No Surprises Act, the rule conflicts with the unambiguous terms of the act, the departments improperly bypassed notice and comment in implementing the challenged portions of the rule, and vacatur and remand is the proper remedy.”

Read the full decision here.

Anthony Vecchione

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”